DexCom (DXCM) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-58.2M
Depreciation and amortization	11.4M
Share-based compensation	81.7M
Accretion and amortization related to investments, net	200K
Accretion of non-cash interest expense related to convertible notes
Loss on debt extinguishment upon conversion of convertible debt
Amortization of debt issuance costs	100K
Accounts receivable	-2.2M
Inventory	-8.9M
Prepaid and other assets	-4.1M
Restricted cash
Accounts payable and accrued liabilities	18.6M
Accrued payroll and related expenses	2M
Deferred revenue	-300K
Deferred rent and other liabilities	2.2M
Net cash used in operating activities	42.9M
Purchase of available-for-sale marketable securities	-30.1M
Proceeds from the maturity of available-for-sale marketable securities
Purchase of property and equipment	-38.1M
Net cash used in investing activities	-38.6M
Net proceeds from issuance of common stock	9.9M
Repayment of equipment loan
Net cash provided by financing activities	7.6M
Effect of exchange rate changes on cash and cash equivalents	-300K
Increase in cash and cash equivalents	11.6M
Cash and cash equivalents, beginning of period	86.1M
Cash and cash equivalents, end of period	97.7M
Conversion of convertible notes to common stock

Entities mentioned with DXCM

View All Entities